Table 1: Baseline characteristics.

CharacteristicImatinib + BSC
( )
BSC alone
(
P value

Age (years)
 Median (range)54.5 (48–7)62.5 (41–73)
Sex
 Male880.701
 Female64
ECOG PS
 1840.220
 265
 301
 402
Change in PS*
 Better100.003
 Worse18
 No change124
Primary site of cancer
 Stomach530.913
 Small intestine77
 Rectum11
 Other11
Metastatic sites
 Liver580.728
 Peritoneum99
 Other32
Duration of initial treatment with imatinib, months
 Median (range)41 (20–79)19.5 (1–49)
Best response to initial treatment with imatinib
 CR340.351
 PR32
 SD12
 PD34
 NE40
Reason for cessation of initial imatinib treatment
 Resistance14110.462
 Intolerance01
Duration of sunitinib therapy, months
 Median (range)7.5 (3–17)6 (1–34)

BSC: best supportive care; ECOG PS: Eastern Cooperative Oncology Group Performance Status; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NE: not evaluable.
*Compared with presunitinib status.
Fisher’s exact test.